Abstract |
A leukemia-associated antigen, CAMAL, shown to be present in bone marrow (BM) cells from patients with acute nonlymphoblastic leukemia ( ANLL) even during remission, has been examined using indirect immunoperoxidase and a monoclonal antibody, CAMAL-1. We are ending the third year of an ongoing blind study designed to monitor the number of BM cells expressing the CAMAL protein ( CAMAL BM value) in ANLL patients over the course of their disease. Results thus far have revealed that the CAMAL BM value in individual patients often changed significantly post- chemotherapy. This change appeared to be a useful prognostic marker in many instances. ANLL patients at initial presentation whose CAMAL BM values increased or stayed the same post- chemotherapy had significantly (p less than 0.025) shorter remission lengths (x = 6.8 months, n = 24) than those whose CAMAL BM values decreased (x = 19.2 months, n = 10). There are indications that increasing CAMAL BM values during remission occur prior to clinical relapse.
|
Authors | P M Logan, S Whitney, S Naiman, J G Levy |
Journal | Leukemia research
(Leuk Res)
Vol. 12
Issue 1
Pg. 19-24
( 1988)
ISSN: 0145-2126 [Print] England |
PMID | 3282127
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, Differentiation, Myelomonocytic
- Antigens, Neoplasm
- Biomarkers, Tumor
- common myelogenous leukemia-associated antigen
|
Topics |
- Acute Disease
- Antigens, Differentiation, Myelomonocytic
- Antigens, Neoplasm
(analysis)
- Biomarkers, Tumor
(analysis)
- Bone Marrow
(analysis, pathology)
- Bone Marrow Transplantation
- Double-Blind Method
- Humans
- Leukemia
(mortality, pathology, therapy)
- Neoplasm Recurrence, Local
- Prognosis
- Remission Induction
|